Structure Therapeutics Inc.
GPCRNASDAQHealthcareBiotechnology
Previous close
$49.09
−$1.43 · -2.83%
Pre-market
$49.35
+$0.26 · +0.53%
Aug 24, 5:12 AM ET
GPCR company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
40
Expensive
Momentum
55
Neutral
Sentiment
62
Bullish
Risk resilience
48
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteStructure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Raymond C. Stevens
- Listed since
- Feb 3, 2023
- Employees
- 233
Market position
Day range
Current $49.09
52-week range
Current $49.09
- Open
- $50.61
- Previous close
- $50.52
- Volume
- 592.57K
- 0.79× average
- Average volume
- 752.17K
- Average daily volume
- Market cap
- 2.83B USD
- Beta
- -1.51
- Market reference 1
- 50-day average
- $50.0699
- -1.96% below average
- 200-day average
- $53.6977
- -8.58% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 3.32B USD
- P/E (TTM)
- -16.2×
- P/B (TTM)
- 2.63×
- P/S (TTM)
- 0×
- EV / EBITDA
- -24.3×
- Earnings yield
- -3.43%
- Free cash flow yield
- -5.48%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -9.31%
- Return on assets
- -8.91%
- Return on invested capital
- -18.88%
Financial health
- Debt / equity
- 0×
- Current ratio
- 24.81×
- Altman Z-score
- 23.84
- Piotroski F-score
- 1 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 3.9M USD | — | — | — | — |
| Gross profit | −3.9M USD | — | — | — | — |
| Research and development | 225.26M USD | 108.81M USD | 70.1M USD | 36.19M USD | 29.11M USD |
| Selling, general, and administrative | 61.55M USD | 49.41M USD | 32.67M USD | 16.37M USD | 8.59M USD |
| Operating expenses | 283.67M USD | 158.23M USD | 102.78M USD | 52.56M USD | 37.7M USD |
| Interest income | 35.97M USD | 36.03M USD | 13.38M USD | 1.26M USD | 122 USD |
| Interest expense | — | — | 13.39M USD | — | 122.16K USD |
| Depreciation and amortization | 3.9M USD | 992K USD | 295K USD | 277K USD | 72K USD |
| Operating income | −287.57M USD | −158.23M USD | −102.78M USD | −52.56M USD | −37.7M USD |
| Net income | −141.2M USD | −122.53M USD | −89.62M USD | −51.32M USD | −40.01M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 45%
- 5 beats, 6 misses, 0 met estimates
- Average EPS surprise
- -4.53%
- 11 comparable reports
- Latest EPS result
- -0.49
- Estimate -0.39 · Miss by 25.64%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$108.67
121.37% upsideRating distribution
14 ratingsRecent analyst actions
GPCR news
GPCR peers
ETFs holding GPCR
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB22.13M0.21%10.75B USD0.44%$213.56+1.29%
ALPS Medical Breakthroughs ETFSBIO4.09M1.73%236.37M USD0.50%$69.11+0.80%
American Century Focused Dynamic Growth ETFFDG3.32M0.81%415.56M USD0.45%$132.03+1.22%
Roundhill Investments - GLP-1 & Weight Loss ETFOZEM1.75M2.68%65.24M USD0.59%$33.8081+0.16%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX1.74M0.25%685.65M USD0.65%$72.22+0.25%
TrueShares Technology, AI and Deep Learning ETFLRNZ1.62M4.05%40.73M USD0.68%$62.725+1.12%
Fidelity Fundamental Small-Mid Cap ETFFFSM1.6M0.12%1.5B USD0.43%$37.31+0.84%
Fidelity Nasdaq Composite Index ETFONEQ1.05M0.01%10.35B USD0.21%$103.14+0.41%iShares Biotechnology ETFIBB- Market value
- 22.13M
- Weight
- 0.21%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
ALPS Medical Breakthroughs ETFSBIO- Market value
- 4.09M
- Weight
- 1.73%
- AUM
- 236.37M USD
- Expense ratio
- 0.50%
- Price / 1D
- $69.11+0.80%
American Century Focused Dynamic Growth ETFFDG- Market value
- 3.32M
- Weight
- 0.81%
- AUM
- 415.56M USD
- Expense ratio
- 0.45%
- Price / 1D
- $132.03+1.22%
Roundhill Investments - GLP-1 & Weight Loss ETFOZEM- Market value
- 1.75M
- Weight
- 2.68%
- AUM
- 65.24M USD
- Expense ratio
- 0.59%
- Price / 1D
- $33.8081+0.16%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX- Market value
- 1.74M
- Weight
- 0.25%
- AUM
- 685.65M USD
- Expense ratio
- 0.65%
- Price / 1D
- $72.22+0.25%
TrueShares Technology, AI and Deep Learning ETFLRNZ- Market value
- 1.62M
- Weight
- 4.05%
- AUM
- 40.73M USD
- Expense ratio
- 0.68%
- Price / 1D
- $62.725+1.12%
Fidelity Fundamental Small-Mid Cap ETFFFSM- Market value
- 1.6M
- Weight
- 0.12%
- AUM
- 1.5B USD
- Expense ratio
- 0.43%
- Price / 1D
- $37.31+0.84%
Fidelity Nasdaq Composite Index ETFONEQ- Market value
- 1.05M
- Weight
- 0.01%
- AUM
- 10.35B USD
- Expense ratio
- 0.21%
- Price / 1D
- $103.14+0.41%
Continue in GoAI
Research GPCRresearch.disclaimer